Developer docs
API playgroundTry for free, no card

Search company profiles

Fermenta Biotech

Full company profile

uuid0006xwu

Namestring
Fermenta Biotech
Legal namestring
Fermenta Biotech Limited
Company typeenum
Public
Founded yearint
1951
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersThane, India
HQ citystring
Thane
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Vitamin D3 manufacturing, pharmaceutical ingredients, nutritional premixes, biotech enzymes, animal feed additives
Industry2 codes
PRIMARYAFAJAKAA
Vitamins (A, B-Complex, C, D, E, K; Premixes)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)
SECONDARYCRADAGAB
Vitamins & Minerals (Single Nutrients)
NAICS code1 code
  • Food Manufacturing311
SIC code1 code
  • Food And Kindred Products2000
Product category
Vitamin D3 and Nutritional Ingredients Manufacturing
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Vitamin D3 and Related Ingredients
TypeOne Time License
Description

Manufacture and global supply of Vitamin D3 (cholecalciferol) in multiple variants — crystalline, oil, resin in oil, cold water dispersible (CWD), and feed grade powder — for pharmaceuticals, dietary/nutritional supplements, food fortification, feed, veterinary, and rodenticide applications. Also includes niche APIs such as Phenyramidol and Silicon Dioxide, Vitamin K1, Vitamin E50, and fish oil cholesterol.

fermentabiotech.com
2Biotechnology / Enzyme Portfolio
TypeLicensing Royalties
Description

Proprietary enzyme technologies (Fermase PS 250, Penicillin G Acylase, Dilbeads) delivered across the biopharmaceutical product lifecycle for manufacturing beta-lactam antibiotics, fine chemicals, bio-plastics, and cosmetics. Revenue from enzyme product sales and technology licensing.

fermentabiotech.com
3Nutritional Premixes and Fortified Rice Kernel
TypeOne Time License
Description

Customised premixes for food fortification (staple food fortification, dietary supplements, RUTF, RUSF, bakery, confectionery, beverages, health food drinks) and Fortified Rice Kernel (FRK) manufacturing. Revenue from premix product sales and toll manufacturing.

fermentabiotech.com
4Environmental Solutions
TypeProfessional Services
Description

Comprehensive wastewater treatment solutions including design, engineering, procurement, construction, and operation & maintenance of STPs, WTPs, and ETPs. The environmental solutions business was sold to the wholly-owned subsidiary Fermenta Environment Solutions Private Limited (FESPL) on a slump sale basis effective October 1, 2025.

fermentabiotech.com
5Real Estate
TypeLicensing Royalties
Description

Property development and rental income from Thane One IT park (~200,000 sq ft leasable area, 100% occupied) and freehold land of ~5.5 acres. Tenants include Tata Technologies, Ashok Leyland, Samsung India, and Datamark BPO.

fermentabiotech.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1VITADEE 100 SD
Description

Spray-Dried variant of Vitamin D3 that received CEP from EDQM, enabling accelerated global growth.

fermentabiotech.com
+6 more records
Core offering1 text field

Fermenta Biotech Limited manufactures and sells Vitamin D3 (cholecalciferol), other vitamins (A, E), proprietary enzymes, and customized nutritional premixes for pharmaceutical, dietary supplement, food, and animal feed manufacturers globally. The company operates integrated manufacturing facilities in Kullu (Himachal Pradesh) and Dahej (Gujarat), India, and exports to 50-60 countries through subsidiaries in the USA and Germany.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Vitamin D3 Human Nutrition segment volumes grew 46% over 9MFY25, with 9MFY26 revenue reaching INR 413.6-421.2 crore and EBITDA up 86% YoY.
+3 more records
Product overview1 text field

Fermenta Biotech is a manufacturer of pharmaceutical ingredients and nutritional products organized into five business segments: Vitamins and Other Ingredients (core business including Vitamin D3 variants, Vitamin K1, Vitamin E50, and niche APIs like Phenyramidol and Silicon Dioxide), Biotechnology (enzyme portfolio including Fermase enzymes and Novel Penicillin G Acylase for antibiotic synthesis), Nutrition (customized premixes, Fortified Rice Kernel, and Vitamin AD2 premix), Environmental Solutions (wastewater treatment plants and related services), and Real Estate (Thane One IT park). The company's flagship product is Vitamin D3 (Cholecalciferol) available in multiple variants including crystalline, oil, resin in oil, cold water dispersible, and feed grade powder. Recent product innovations include VITADEE GREEN (plant-based Vitamin D3 with patent protection) and VITADEE 100 SD (spray-dried variant with EDQM CEP). Fermenta also partnered with Solar Foods to introduce Solein protein bars in the US market.

Product and service1 record
1Vitamin D3 (Cholecalciferol)
Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-19
Description

Fermenta partnered with Finnish startup Solar Foods to incorporate Solein CO2-derived protein into gluten-free protein bars for the US market. Solein is a protein ingredient made by feeding microbes on CO2, hydrogen and oxygen, yielding 78% protein content with minimal environmental footprint (1% of conventional meat emissions, 20% of plant proteins). The bars were planned for rollout in Q1 2026 in the US under Fermenta's health and performance nutrition brand.

2Fermenta Environment Solutions Private Limited (FESPL)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-19
Description

Fermenta sold its environmental solutions business operations to its wholly-owned subsidiary Fermenta Environment Solutions Private Limited (FESPL) on a slump sale basis effective October 1, 2025. FESPL was incorporated on May 1, 2025. This transfer enables focused management of the environmental solutions business.

fermentabiotech.com
3Aurigene Pharmaceutical Services Limited (Dr. Reddy's Laboratories)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-12-31
Description

Fermenta exclusively licensed its enzymatic technology for manufacturing Molnupiravir to Aurigene Pharmaceutical Services Limited, a step-down subsidiary of Dr. Reddy's Laboratories Limited. This follows Fermenta's development and patent filing of the enzymatic synthesis process for the COVID-19 drug.

fermentabiotech.com
Strategic tierCoreTypeGTM or Marketing Partner
Description

Fermenta received the Letter of Approval (LOA) from GAIN as a supplier of dry and liquid premix blends. This prestigious certification recognises Fermenta's commitment to global benchmarks of quality, food safety, and nutritional excellence, enabling access to international food fortification programs and public health nutrition initiatives.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Fermenta entered into a strategic Memorandum of Understanding (MoU) with NIFTEM-T to strengthen India's food fortification landscape. The partnership leverages NIFTEM-T's academic and research expertise in food technology alongside Fermenta's manufacturing capabilities in nutritional premixes and fortified rice kernel.

6MUFG Intime India Private Limited
Strategic tierMinorTypeOthers
Description

MUFG Intime India Private Limited serves as the Registrar and Transfer Agent (RTA) for Fermenta Biotech Limited, handling investor service requests, share transfers, IEPF filings, and KYC updates.

fermentabiotech.com
Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

One of the world's largest manufacturers of Vitamin D3 and other vitamins/intermediates based in China. Directly competes with Fermenta in feed-grade and crystalline Vitamin D3 supply across global pharmaceutical, food, and feed channels.

TypeBroad incumbent
Description

Global leader in industrial enzymes and microbial solutions serving pharmaceuticals, food, and bio-based manufacturing. Comparable to Fermenta's Fermase enzyme portfolio and Dilbeads immobilisation technology targeting beta-lactam antibiotic synthesis.

TypeDirect peer
Description

Indian API and contract manufacturer with vitamins, niche APIs, and biocatalysis capabilities serving global pharmaceutical and nutraceutical customers. Closest India-based peer in terms of API/vitamin manufacturing and export orientation.

TypeDirect peer
Description

Global leader in nutritional ingredients including Vitamin D3 (cholecalciferol) and a broad premix/fortification portfolio. Most direct competitor to Fermenta's core vitamin and nutrition business, with overlapping pharma, food, and feed applications.

TypeBroad incumbent
Description

Global nutritional solutions provider offering premixes, customised nutrient blends, and functional ingredients for food, beverage, and supplement brands. Comparable to Fermenta's nutrition/premix and food fortification business, though at much larger scale and broader geographic footprint.

TypeBroad incumbent
Description

Global taste and nutrition company supplying premixes, functional ingredients, and fortification solutions to food and beverage customers. Overlaps with Fermenta's customised premix business serving bakery, beverages, and health food drinks.

TypeRegional player
Description

Large Indian pharmaceutical company with API, generic formulations, and nutraceutical exposure. Comparable as an Indian-listed pharma/ingredients peer operating across regulated global markets, although Aurobindo is far larger and more diversified.

TypeEmerging player
Description

Finnish startup producing Solein CO2-derived protein; Fermenta has a strategic partnership to incorporate Solein into US-market gluten-free protein bars. Comparable as an emerging nutrition/ingredient partner rather than a direct competitor, sharing the plant-based, sustainability-led value proposition.

9Taizhou Hisound Chemical
TypeDirect peer
Description

Chinese specialty chemical producer focused on Vitamin D3 and cholecalciferol derivatives for nutraceutical and pharmaceutical applications. Direct peer in the global Vitamin D3 bulk API market where pricing and capacity decisions shape Fermenta's economics.

TypeBroad incumbent
Description

Major global chemicals and nutrition company producing vitamins (including D3), enzymes, and a wide portfolio of nutritional and food ingredients. Overlaps with Fermenta in vitamins, enzymes, and premixes but operates across many more verticals.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance12 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Fermenta Biotech

Vitamin D3 and Nutritional Ingredients Manufacturingfermentabiotech.com

Fermenta Biotech firmographics

Firmographics
Name
Fermenta Biotech
Legal name
Fermenta Biotech Limited
Website
https://fermentabiotech.com
Company type
Public
Founded year
1951
Operating status
Operating
Headcount range
501–1,000 employees
Ownership category
akta.pro rank

Fermenta Biotech industry classification

Industry
Product category
Vitamin D3 and Nutritional Ingredients Manufacturing
NAICS
Food Manufacturing (311)
SIC
Food And Kindred Products (2000)
akta.pro industry
PRIMARYAFAJAKAA
Vitamins (A, B-Complex, C, D, E, K; Premixes)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)
SECONDARYCRADAGAB
Vitamins & Minerals (Single Nutrients)

Keywords

  • Vitamin D3 manufacturing
  • Pharmaceutical ingredients
  • Nutritional premixes
  • Biotech enzymes
  • Animal feed additives

Where Fermenta Biotech is headquartered

Location

Headquarters

HQ city
Thane
HQ country
India
HQ region
Asia

Offices8 records

Markets served

Fermenta Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales

Revenue model

  1. Vitamin D3 and Related Ingredients: Manufacture and global supply of Vitamin D3 (cholecalciferol) in multiple variants — crystalline, oil, resin in oil, cold water dispersible (CWD), and feed grade powder — for pharmaceuticals, dietary/nutritional supplements, food fortification, feed, veterinary, and rodenticide applications. Also includes niche APIs such as Phenyramidol and Silicon Dioxide, Vitamin K1, Vitamin E50, and fish oil cholesterol.
  2. Biotechnology / Enzyme Portfolio: Proprietary enzyme technologies (Fermase PS 250, Penicillin G Acylase, Dilbeads) delivered across the biopharmaceutical product lifecycle for manufacturing beta-lactam antibiotics, fine chemicals, bio-plastics, and cosmetics. Revenue from enzyme product sales and technology licensing.
  3. Nutritional Premixes and Fortified Rice Kernel: Customised premixes for food fortification (staple food fortification, dietary supplements, RUTF, RUSF, bakery, confectionery, beverages, health food drinks) and Fortified Rice Kernel (FRK) manufacturing. Revenue from premix product sales and toll manufacturing.
  4. Environmental Solutions: Comprehensive wastewater treatment solutions including design, engineering, procurement, construction, and operation & maintenance of STPs, WTPs, and ETPs. The environmental solutions business was sold to the wholly-owned subsidiary Fermenta Environment Solutions Private Limited (FESPL) on a slump sale basis effective October 1, 2025.
  5. Real Estate: Property development and rental income from Thane One IT park (~200,000 sq ft leasable area, 100% occupied) and freehold land of ~5.5 acres. Tenants include Tata Technologies, Ashok Leyland, Samsung India, and Datamark BPO.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Fermenta Biotech product offering

Product offering

Core offering

Fermenta Biotech Limited manufactures and sells Vitamin D3 (cholecalciferol), other vitamins (A, E), proprietary enzymes, and customized nutritional premixes for pharmaceutical, dietary supplement, food, and animal feed manufacturers globally. The company operates integrated manufacturing facilities in Kullu (Himachal Pradesh) and Dahej (Gujarat), India, and exports to 50-60 countries through subsidiaries in the USA and Germany.

Product overview

Fermenta Biotech is a manufacturer of pharmaceutical ingredients and nutritional products organized into five business segments: Vitamins and Other Ingredients (core business including Vitamin D3 variants, Vitamin K1, Vitamin E50, and niche APIs like Phenyramidol and Silicon Dioxide), Biotechnology (enzyme portfolio including Fermase enzymes and Novel Penicillin G Acylase for antibiotic synthesis), Nutrition (customized premixes, Fortified Rice Kernel, and Vitamin AD2 premix), Environmental Solutions (wastewater treatment plants and related services), and Real Estate (Thane One IT park). The company's flagship product is Vitamin D3 (Cholecalciferol) available in multiple variants including crystalline, oil, resin in oil, cold water dispersible, and feed grade powder. Recent product innovations include VITADEE GREEN (plant-based Vitamin D3 with patent protection) and VITADEE 100 SD (spray-dried variant with EDQM CEP). Fermenta also partnered with Solar Foods to introduce Solein protein bars in the US market.

Differentiator

Problem solved

Functional benefit

Brands

  • VITADEE 100 SD: Spray-Dried variant of Vitamin D3 that received CEP from EDQM, enabling accelerated global growth.
  • VITADEE Green
  • Thane One
  • Fermase PS 250
  • Fermase PA 850
  • Fermase PAR 450
  • Dilbeads

Products and services

  • Vitamin D3 (Cholecalciferol)

Quantifiable outcome

  • Vitamin D3 Human Nutrition segment volumes grew 46% over 9MFY25, with 9MFY26 revenue reaching INR 413.6-421.2 crore and EBITDA up 86% YoY.
  • +3 more outcomes

Companies that use Fermenta Biotech

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles3 records

Fermenta Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Fermenta Biotech partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Solar FoodscoreStrategic or Co-development Partner · 19 March 2026Fermenta partnered with Finnish startup Solar Foods to incorporate Solein CO2-derived protein into gluten-free protein bars for the US market. Solein is a protein ingredient made by feeding microbes on CO2, hydrogen and oxygen, yielding 78% protein content with minimal environmental footprint (1% of conventional meat emissions, 20% of plant proteins). The bars were planned for rollout in Q1 2026 in the US under Fermenta's health and performance nutrition brand.
  • Fermenta Environment Solutions Private Limited (FESPL)coreStrategic or Co-development Partner · 19 September 2025Fermenta sold its environmental solutions business operations to its wholly-owned subsidiary Fermenta Environment Solutions Private Limited (FESPL) on a slump sale basis effective October 1, 2025. FESPL was incorporated on May 1, 2025. This transfer enables focused management of the environmental solutions business.
  • Aurigene Pharmaceutical Services Limited (Dr. Reddy's Laboratories)coreStrategic or Co-development Partner · 31 December 2022Fermenta exclusively licensed its enzymatic technology for manufacturing Molnupiravir to Aurigene Pharmaceutical Services Limited, a step-down subsidiary of Dr. Reddy's Laboratories Limited. This follows Fermenta's development and patent filing of the enzymatic synthesis process for the COVID-19 drug.
  • Global Alliance for Improved Nutrition (GAIN)coreGTM or Marketing PartnerFermenta received the Letter of Approval (LOA) from GAIN as a supplier of dry and liquid premix blends. This prestigious certification recognises Fermenta's commitment to global benchmarks of quality, food safety, and nutritional excellence, enabling access to international food fortification programs and public health nutrition initiatives.
  • National Institute of Food Technology, Entrepreneurship and Management – Thanjavur (NIFTEM-T)minorStrategic or Co-development PartnerFermenta entered into a strategic Memorandum of Understanding (MoU) with NIFTEM-T to strengthen India's food fortification landscape. The partnership leverages NIFTEM-T's academic and research expertise in food technology alongside Fermenta's manufacturing capabilities in nutritional premixes and fortified rice kernel.
  • MUFG Intime India Private LimitedminorOthersMUFG Intime India Private Limited serves as the Registrar and Transfer Agent (RTA) for Fermenta Biotech Limited, handling investor service requests, share transfers, IEPF filings, and KYC updates.

Scale indicators13 records

Recent moves11 records

Expansion highlights6 records

Fermenta Biotech competitors and assessment

Company assessment

Direct peers

  • Zhejiang NHU Company: One of the world's largest manufacturers of Vitamin D3 and other vitamins/intermediates based in China. Directly competes with Fermenta in feed-grade and crystalline Vitamin D3 supply across global pharmaceutical, food, and feed channels.
  • Dishman Carbogen Amcis: Indian API and contract manufacturer with vitamins, niche APIs, and biocatalysis capabilities serving global pharmaceutical and nutraceutical customers. Closest India-based peer in terms of API/vitamin manufacturing and export orientation.
  • dsm-firmenich: Global leader in nutritional ingredients including Vitamin D3 (cholecalciferol) and a broad premix/fortification portfolio. Most direct competitor to Fermenta's core vitamin and nutrition business, with overlapping pharma, food, and feed applications.
  • Taizhou Hisound Chemical: Chinese specialty chemical producer focused on Vitamin D3 and cholecalciferol derivatives for nutraceutical and pharmaceutical applications. Direct peer in the global Vitamin D3 bulk API market where pricing and capacity decisions shape Fermenta's economics.

Broad incumbents

  • Novonesis (formerly Novozymes): Global leader in industrial enzymes and microbial solutions serving pharmaceuticals, food, and bio-based manufacturing. Comparable to Fermenta's Fermase enzyme portfolio and Dilbeads immobilisation technology targeting beta-lactam antibiotic synthesis.
  • Glanbia Nutritionals: Global nutritional solutions provider offering premixes, customised nutrient blends, and functional ingredients for food, beverage, and supplement brands. Comparable to Fermenta's nutrition/premix and food fortification business, though at much larger scale and broader geographic footprint.
  • Kerry Group: Global taste and nutrition company supplying premixes, functional ingredients, and fortification solutions to food and beverage customers. Overlaps with Fermenta's customised premix business serving bakery, beverages, and health food drinks.
  • BASF: Major global chemicals and nutrition company producing vitamins (including D3), enzymes, and a wide portfolio of nutritional and food ingredients. Overlaps with Fermenta in vitamins, enzymes, and premixes but operates across many more verticals.

Regional players

  • Aurobindo Pharma: Large Indian pharmaceutical company with API, generic formulations, and nutraceutical exposure. Comparable as an Indian-listed pharma/ingredients peer operating across regulated global markets, although Aurobindo is far larger and more diversified.

Emerging players

  • Solar Foods: Finnish startup producing Solein CO2-derived protein; Fermenta has a strategic partnership to incorporate Solein into US-market gluten-free protein bars. Comparable as an emerging nutrition/ingredient partner rather than a direct competitor, sharing the plant-based, sustainability-led value proposition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Fermenta Biotech social profiles

Digital presence

Fermenta Biotech compliance and trust

Trust signal

Compliance12 records

Fermenta Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Fermenta Biotech leadership team

Management profile

Number of profiles

Profiles3 records

Fermenta Biotech subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Fermenta Biotech funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Fermenta Biotech M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fermenta Biotech

What does Fermenta Biotech do?

Fermenta Biotech Limited manufactures and sells Vitamin D3 (cholecalciferol), other vitamins (A, E), proprietary enzymes, and customized nutritional premixes for pharmaceutical, dietary supplement, food, and animal feed manufacturers globally. The company operates integrated manufacturing facilities in Kullu (Himachal Pradesh) and Dahej (Gujarat), India, and exports to 50-60 countries through subsidiaries in the USA and Germany.

Is Fermenta Biotech a public or private company?

Fermenta Biotech is a public company. It is classified as public and is currently operating.

When was Fermenta Biotech founded?

Fermenta Biotech was founded in 1951. It employs 501 to 1,000 people.

Where is Fermenta Biotech based?

Fermenta Biotech is headquartered in Thane, India, in the Asia region.

How does Fermenta Biotech make money?

Five revenue lines are on record. Vitamin D3 and Related Ingredients are the primary driver. The others are biotechnology / Enzyme Portfolio, nutritional Premixes and Fortified Rice Kernel, environmental Solutions and real Estate.

Who are Fermenta Biotech's main competitors?

Direct peers on record are Zhejiang NHU Company, Dishman Carbogen Amcis, dsm-firmenich and Taizhou Hisound Chemical. Broad incumbents are Novonesis (formerly Novozymes), Glanbia Nutritionals, Kerry Group and BASF. Aurobindo Pharma is listed as a regional player. Solar Foods is listed as an emerging player.

Does Fermenta Biotech have an API?

No public API is recorded for Fermenta Biotech.

What industry is Fermenta Biotech in?

Fermenta Biotech's product category is Vitamin D3 and Nutritional Ingredients Manufacturing. Its primary akta.pro industry code is AFAJAKAA, Vitamins (A, B-Complex, C, D, E, K; Premixes), with a secondary code of CRADAGAB, Vitamins & Minerals (Single Nutrients). Its NAICS code is 311 and its SIC code is 2000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ScanXFermenta Biotech to host investor meeting in Dahej on Oct 15Fermenta Biotech will hold a group investor meeting on October 15, 2026, in Dahej, Gujarat, in physical mode. The company disclosed the details on October 12, 2026, and confirmed no unpublished price-sensitive information will be discussed, complying with SEBI regulations.ScanXFermenta Biotech promoter Preeti Thakkar sells 3.96% stakeFermenta Biotech promoter Preeti Thakkar sold 11,65,938 shares on September 28, 2026, representing 3.96% of the company's equity. The sale reduced her holding from 7.61% to 3.65%, and the transaction was disclosed under SEBI regulations.ScanXFermenta Biotech hosts one-to-one investor meeting in Mumbai on Sep 24Fermenta Biotech will host a one-to-one physical investor meeting in Mumbai on September 24, 2026. The company confirmed no unpublished price-sensitive information will be discussed, and the disclosure was made under SEBI LODR Regulations. The meeting is part of ongoing investor engagement.ScanXFermenta Biotech signs exclusive licence with VIT for Vitamin B12 techFermenta Biotech signed an exclusive licence with Vellore Institute of Technology (VIT) for natural in-situ Vitamin B12 fortification in fermented foods. The technology, developed by VIT's Centre for BioSeparation Technology, shows about 80% retention after cooking. Next steps include regulatory evaluation and commercial solution development.ScanXFermenta Biotech shareholders approve ₹3.75 dividend, director reappointmentShareholders of Fermenta Biotech approved a final dividend of ₹3.75 per share and the reappointment of Non-Executive Director Ms. Rajeshwari Datla at the company's 74th Annual General Meeting on August 11, 2026. The meeting also ratified material related-party transactions with Fermenta USA LLC up to ₹100 crore. This approval comes despite the company reporting a 55.8% year-over-year drop in Q1FY26 consolidated net profit.ScanXFermenta Biotech FY26 Results: Revenue hits record ₹548 croreFermenta Biotech reported record consolidated revenue of ₹548 crore for FY26, driven by a 26% growth in core operations and a 44% increase in Core EBITDA to ₹120 crore. The company's Board approved ₹110 crore in capital expenditure for new capacity at its Dahej facility, specifically targeting plant-source Vitamin D3 and enzymes.Business StandardFermenta Biotech consolidated net profit declines 55.38% in the June 2026 quarterFermenta Biotech reported a net profit decline of 55.38% in the quarter ending June 2026, with profits amounting to Rs 9.74 crore compared to Rs 21.83 crore in the same quarter of 2025. Additionally, sales decreased by 10.60%, totaling Rs 121.82 crore down from Rs 136.26 crore in the previous year. The overall financial performance reflects significant declines in both profit and sales year-over-year.ScanXFermenta Biotech Q1 Results: Net Profit Down 56% YoY To ₹9.5 CroreFermenta Biotech's Q1FY27 financial results show a 56% decline in net profit to ₹9.5 crore, driven by lower animal nutrition realizations and absence of insurance gains. Revenue decreased by 12% YoY to ₹124.3 crore, with some growth in human nutrition volumes and new product approvals offering potential growth avenues.BusinessLineFermenta Biotech lists on NSEFermenta Biotech Ltd listed its equity shares on the National Stock Exchange of India (NSE) on August 4, 2026, marking a milestone in the company's 75-year history. The company, one of the world's largest manufacturers of active pharmaceutical ingredient in Vitamin D3, has 294,309,87 equity shares of face value ₹5 each now listed on NSE while maintaining its BSE listing since 1977. Vitamin D sales account for over 70% of Fermenta's total revenue of ₹551 crore for the year ended March 2026, with customers across more than 60 countries and recent FSSAI approval for its plant-source Vitamin D3 ingredient.Business StandardShares of Fermenta Biotech list on NSEFermenta Biotech announced the successful listing of its equity shares on the National Stock Exchange of India (NSE) effective August 4, 2026. A total of 2,94,30,987 equity shares with face value of Rs 5 each have been admitted to dealings on the NSE under the symbol FERMENTA. The company's shares will continue to remain listed on the BSE under Scrip Code 506414.